JA Brand Name 2080526.pdf

Justification for Other than Full and Open Competition at or Below the Simplified Acquisition Threshold

BRAND NAME

Acquistion description: Invitrogen Reagents

I . Identification of the agency and contracting activity

DHHS, NIH, NIAID,VRC

Address of the requesting lab/office: 40 Convent Dr, Bethesda, MD 20892

II. Description of the project, and supplies or services required to meet the agency’s needs

A. Project Background of the lab (Mission of the lab) The Vaccine Research Center at the National Institutes of Health will conduct research that facilitates the development of effective vaccines. Towards this end, our goal has been to develop vaccine and passive immunotherapies, such as monoclonal antibodies, that can be used as both preventative treatments and acute therapies. This project enables the production of vaccine candiates, monoclonal antibodies and proteins used in assays to evaluate the qualitity of the vaccinations and antibodies being evaluated.

B. Project Description of the requirement (what and how item/service is needed /used) The Vaccine Research Center at the National Institutes of Health develops vaccines and monoclonal antibody therapies for the treatment of infectious diseases. The Yeast Engineering Technology & Immunobiology (YETI) Core evaluates immune responses, performs antibody discovery and engineers antibodies and immunogens against COVID-19. YETI provide a high-throughput droplet-based single cell overlap extension RT-PCR using a well established protocol that requires the use of Superscript III One Step Hi Fi enzyme and Superase IN RNA inhibitor.

C. Description of the supplies/services to be purchased Multiple deliveries of Superscript III One Step HiFi and Superase IN

Manufacturer:

Invitrogen Life Technologies Corporation 3175 Staley Road Grand Island, New York 14072

III. Identification of the statutory authority permitting other than full and open competition ☒ 41 USC 3304(a)(1) and FAR P ar t 6 . 302- 1 : Brand Name

IV. Demonstration that the proposed brand name product’s salient characteristics (specific features, qualities and/or the nature of the acquisition) requires use of the authority cited.

YETI provide a high-throughput droplet-based single cell overlap extension RT-PCR using a well established protocol that requires the use of Superscript III One Step Hi Fi enzyme and Superase IN RNA inhibitor. Due the specific needs of this protocol, the two products cannot be substituted for by other reagents.